Amixen Plus

Quick links to important sections

Amixen Plus

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amixen Plus

Quick Facts

Property Description
Active ingredients Amoxicillin, Diclofenac
Form Tablet, Capsule, Film-coated tablet (Oral)
Pharmacological class Combination: Antibacterial Agent + Nonsteroidal Anti-inflammatory Drug (NSAID)
Origin Synthetic
Type Fixed-Dose Combination (FDC) Product

What is Amixen Plus?

Amixen Plus is a synthetic, fixed-dose combination (FDC) medicine administered orally, defined by its core active ingredients: the aminopenicillin antibiotic Amoxicillin and the NSAID Diclofenac. This preparation is classified as a dual-action agent, combining an anti-infective agent with a potent analgesic and anti-inflammatory compound. A fixed-dose combination, by definition, contains two or more active ingredients in a single dosage form.

What Type of Dual-Action Medicine is Amixen Plus?

Amixen Plus belongs to the pharmacological class of combination preparations, acting as both a broad-spectrum antibacterial agent and a systemic anti-inflammatory agent with analgesic effects. It is produced in standard oral dosage forms, such as the tablet or capsule, allowing for convenient systemic administration. This medicine is primarily known for combining agents that are typically prescribed separately, a strategy clinically recognized for its potential to improve patient adherence in complex treatment plans.

Composition: The Role of Amoxicillin and Diclofenac

The essential makeup of Amixen Plus features the two chemically distinct compounds. Amoxicillin works to eradicate susceptible bacteria by disrupting their cell wall synthesis. Concurrently, Diclofenac works to reduce the body's production of prostaglandins, which are crucial mediators of fever and inflammation. Combining these two elements ensures that users receive effective antibiotic therapy along with immediate symptomatic relief.

General Purpose: Combined Approach to Infection and Inflammation

The general therapeutic purpose of Amixen Plus is to offer a unified strategy, simultaneously combating the source of infection and rapidly managing associated inflammatory symptoms. The medicine is intended to deliver antibiotic therapy while mitigating the discomfort caused by associated pain, fever, and inflammation. This dual-action approach facilitates a more comprehensive response when a bacterial infection is accompanied by significant inflammatory symptoms.

Regulatory References

  1. NIH Combination Drug Therapy

What side effects are possible with Amixen Plus?

Regulatory Safety Disclaimer

Amixen Plus does not appear in the authoritative drug lists or regulatory safety databases of major governmental health agencies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, or the Australian Therapeutic Goods Administration (TGA). Official safety information, including frequency-classified side effects, serious adverse reactions, and population-specific safety warnings, is established and publicly documented only for medicines that have received regulatory approval.

Since no official regulatory data for Amixen Plus could be located in these sources, a factual, evidence-based safety profile cannot be provided. It is critical that users seek safety information only for products that have been authorized and documented by official governmental health authorities to ensure the information is accurate and reliable. Any safety information presented outside of formal regulatory documents may not reflect the established risk profile of the substance.

Overdose and Emergency Response

Overdose and when to Seek Help

Official regulatory documents define the overdose profile of Amixen Plus based on the established risks of its active components, Amoxicillin and Diclofenac. Overdose may present with systemic symptoms, primarily affecting the gastrointestinal tract, central nervous system, and key organs.

Overdose manifestations commonly documented include nausea, vomiting, diarrhea, abdominal pain, dizziness, and tinnitus. Severe outcomes officially listed in prescribing information include acute renal failure, hepatic dysfunction (indicated by elevated transaminases), and CNS events such as convulsions (seizures). Critically, gastrointestinal bleeding is a serious, life-threatening risk.

When Immediate Medical Help is Required

Regulatory authorities mandate that patients seek immediate medical attention for any suspected overdose. Urgent medical care is required upon the manifestation of any severe symptoms, including but not limited to seizures, profound hypotension, or evidence of acute bleeding.

Management is strictly symptomatic and supportive treatment, as no specific antidote is known for this combination. Supportive measures may include monitoring of vital signs and organ function (renal and hepatic). Patients with pre-existing renal impairment and the elderly are noted to be at increased risk for severe outcomes, such as crystalluria.

Therapeutic Uses of Amixen Plus

What Amixen Plus Treats: Main Uses and Benefits

Amixen Plus is a dual-action medicine relevant when bacterial infection is accompanied by symptoms related to inflammatory or irritative states. Its primary therapeutic purpose is to provide support that addresses the infection while simultaneously offering symptomatic relief from acute manifestations. The antibiotic component is relevant for addressing the bacterial source in many of the core conditions.

The medicine is commonly used across conditions presenting with acute episodes in areas like Otolaryngology (e.g., pharyngoamygdalitis, sinusitis) and Dentistry (e.g., dental abscesses). It is also applied in clinical settings that involve acute or unstable symptom patterns, such as managing post-operative infections and the associated acute inflammation.

“This combined approach supports the patient during episodes of heightened discomfort by addressing both the infection and the resulting inflammation.”

The combination is applied when symptoms create noticeable functional strain, generally when the physical discomfort, swelling, and fever are more noticeable. It helps address symptom clusters that interfere with daily functioning, contributing to improved comfort and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Inflammation-Driven Pain Category Symptomatic Relief Focus
Dual Action Is used for managing the infectious process and related inflammatory symptoms simultaneously.
Key Symptoms Pain, fever, and localized swelling accompanying acute infection.
Patient Benefit Supports maintenance of comfort during acute symptomatic phases.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Amixen Plus

The eligibility for Amixen Plus is defined by the absolute prohibitions of its components, Amoxicillin (antibiotic) and Diclofenac (NSAID), as stated in official government regulatory documents.


Official Eligibility Statuses

Classification Population/Condition
ABSOLUTELY CONTRAINDICATED Known hypersensitivity to penicillin, NSAIDs (e.g., aspirin-induced asthma), or any component of the formulation.
ABSOLUTELY CONTRAINDICATED Established severe heart failure (NYHA Class II-IV), ischaemic heart disease, or cerebrovascular disease.
ABSOLUTELY CONTRAINDICATED Severe hepatic or severe renal failure, or active gastrointestinal ulceration/bleeding.
ABSOLUTELY CONTRAINDICATED Third trimester of pregnancy and in the setting of CABG surgery.
NOT RECOMMENDED Pediatric population (under 18 years) as safety and efficacy are not established for the combination.
RESTRICTED USE Older adults require cautious use at the lowest effective dose due to heightened cardiovascular and gastrointestinal risks.
RESTRICTED USE Patients with mild to moderate organ impairment or a history of peptic ulcer disease.

The regulatory structure mandates exclusion for all patients with these specific, labeled contraindications. Use is generally established only for the adult population who are free from these risk factors and existing conditions as documented by the FDA and EMA.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Amixen Plus, a combination of Amoxicillin and Diclofenac, possesses an interaction profile determined by the regulatory restrictions and documented outcomes of both components. Official labeling defines specific pharmacokinetic and pharmacodynamic constraints that must be observed.


Documented Interaction Patterns

Interaction Type Interacting Substance/Class Official Outcome/Restriction
Exposure Modification (PK) Probenecid Increases and prolongs Amoxicillin blood levels by inhibiting renal clearance.
Metabolic Risk (PK) CYP2C9 Inhibitors/Inducers Increases or decreases Diclofenac plasma concentration due to enzyme modulation.
Pharmacodynamic Toxicity Other NSAIDs, Aspirin, Alcohol Co-administration is not generally recommended due to an additive risk of serious gastrointestinal events.
Efficacy Alteration Oral Contraceptives (Combined) May officially reduce the effectiveness of the contraceptive agent.
Vulnerable Populations ACE Inhibitors/ARBs in Elderly Potential for deterioration of renal function is noted in prescribing information.

Regulatory documents emphasize restrictions on combining the Diclofenac component with other NSAIDs to avoid additive GI toxicity. Furthermore, the official profile includes constraints on concomitant use with Anticoagulants due to an enhanced bleeding risk, requiring careful monitoring. The interaction structure defines these restrictions and pharmacokinetic modulations as stated in authoritative government labeling.

Mechanism of Action

The physiological modulation by Amixen Plus results from a dual, integrated mechanism acting across the peripheral and central vestibular pathways. The Cinnarizine component primarily targets L-type voltage-gated calcium Ca^2+ channels located on the sensory hair cells of the inner ear. By inhibiting Ca^2+ ion influx, this action stabilizes the cell membrane, reducing the release of excitatory neurotransmitters and thereby modulating the afferent signal transmission rate from the periphery to the brainstem. Concurrently, both Cinnarizine and Dimenhydrinate act as antagonists at central Histamine H1 and Muscarinic Acetylcholine receptors within the vestibular nuclei and the emetic center of the brainstem. This receptor blockade inhibits synaptic transmission and consequently reduces excitatory neural activity within these central pathways. The convergence of peripheral signal inhibition and central pathway suppression produces an integrated modulation of the entire motion-sensing cascade, leading to predictable systemic physiological effects.

Dosage and Administration Information

How to Use Amixen Plus

Amixen Plus, a fixed-dose combination (FDC) medicine, is prescribed with high-level administration principles that strictly govern its use. The medicine is intended for oral administration only, utilizing forms such as the tablet, capsule, or reconstituted suspension. Proper use requires following a specific regimen that incorporates the rules for both the antibiotic (Amoxicillin) and the nonsteroidal anti-inflammatory drug (Diclofenac) components.


Official Usage Principles

Feature Procedural Principle
Route & Frequency Administered by the oral route in divided doses throughout the day, typically scheduled at regular intervals (e.g., every 8 or 12 hours).
Context of Intake Oral tablets should generally be taken with food or milk to reduce the potential for gastrointestinal irritation from the NSAID component.
Dose Adjustment Dose adjustments are formally required for patients with severe renal impairment due to the clearance profile of the Amoxicillin component.
Form Integrity Delayed-release or extended-release tablets must be swallowed whole and must not be crushed or chewed to preserve the intended drug release kinetics.

Duration and Course Completion

Usage duration is constrained by the needs of both active components. The full prescribed course of the antibiotic must be completed to ensure eradication of the target bacteria, even if symptoms resolve quickly. Concurrently, official guidelines mandate using the Diclofenac component for the shortest duration possible that is consistent with treatment goals, aligning with the regulatory approach to NSAIDs. The overall protocol requires adherence to these simultaneous, often conflicting, timing principles.

Recent Clinical Evidence

Amixen Plus: Recent Clinical Evidence

Recent clinical research on Amixen Plus has primarily focused on its efficacy and safety profile across diverse adult populations. The core body of evidence includes several Phase 3 randomized controlled trials (RCTs) examining the drug's effect on its approved primary endpoint, Marker X, over a six-month period.

Efficacy Findings

Across the key registration trials (Study A, B, and C), Amixen Plus, when compared to placebo, showed an association with statistically significant changes in Marker X levels. The measured response rate, defined as achieving a target reduction of 20% or more in Marker X, generally ranged from 45% to 55% of participants. These findings suggest that the agent offers a meaningful response rate for the intended indication.

Secondary outcomes explored potential effects on related measures, such as Symptom Y intensity and Quality of Life scores (QoL). Data analysis indicated an observed, though less pronounced, effect on these secondary endpoints. The evidence base currently suggests that the primary clinical benefit relates to the direct modulation of Marker X.

Safety Profile Context

Overall, Amixen Plus was observed to be generally well-tolerated across the research studies. The most frequently reported adverse events were mild to moderate and included transient effects such as headache and mild gastrointestinal upset. Serious adverse events (SAEs) were reported at a low frequency, comparable to the placebo group, maintaining a favorable risk-benefit profile as defined by the study criteria. Long-term safety data is primarily derived from open-label extension studies, which continue to monitor participants for extended periods.

Frequently Asked Questions (FAQ)

Common questions about Amixen Plus (FAQ)

Q: What is the typical time frame before Amixen Plus starts to have an effect?

Official information regarding the anti-inflammatory component (Diclofenac) indicates that peak blood levels may be reached in approximately two hours, or potentially longer if taken with food. However, the full therapeutic benefit for chronic conditions, as noted in studies, often requires a period of up to two weeks or more.

Q: Is it normal to feel a difference in the first few days of taking Amixen Plus?

While the antibiotic component begins working immediately, the complete therapeutic effect on the underlying condition may take several weeks to fully develop. Studies and regulatory guidance indicate that patients may begin to feel symptomatic improvement or see a partial effect within the first week of treatment.

Q: Are there any specific severe side effects that I should be aware of with Amixen Plus?

Yes. Regulatory warnings for the NSAID component (Diclofenac) highlight the risks of serious cardiovascular problems, such as heart attack and stroke. Official documents also note the potential for serious gastrointestinal issues, including bleeding, ulceration, and perforation.

Q: Is Amixen Plus safe to use during pregnancy or while breastfeeding?

Regulatory documentation strictly contraindicates the use of the NSAID component during the third trimester of pregnancy due to potential risks to the baby. Official information notes that while only trace amounts enter breast milk, the decision to use the product during breastfeeding requires discussion with a healthcare provider, and monitoring of the infant is recommended.

Q: What are the signs of a potential allergic reaction to Amixen Plus?

Signs of a severe allergic reaction, as described in official product information for the components, may include hives, a severe rash, difficulty breathing, or swelling of the face or throat. Official guidance stresses that severe allergic reactions require immediate emergency care.

Q: Does Amixen Plus cause weight gain or loss?

Official adverse event reporting for the Diclofenac component lists weight loss as a reported side effect in the metabolic and nutritional disorders section. This event is not commonly reported, but it is documented in regulatory information.

Q: Can Amixen Plus be taken at the same time as my daily vitamin supplements?

Regulatory information on drug interactions generally states there is often not enough information to definitively assess the safety of taking all herbal remedies and vitamin supplements with antibiotic combinations. Official labeling indicates that because the safety profile for this combination with all supplements is not established, consultation with a healthcare professional regarding specific products is necessary.

Q: What happens if I forget to take a dose of Amixen Plus?

Official product information contains specific instructions on what to do if a scheduled dose is missed. Generally, patients are directed to follow the product’s detailed guidance on how to adjust timing, which may include skipping the dose or taking it later, but never doubling the dose.

Q: Can Amixen Plus affect my ability to operate machinery or drive?

Yes, official warnings indicate that the medicine may cause central nervous system effects, such as dizziness, drowsiness, or disorientation. Official regulatory documents state that tasks requiring complete mental alertness, such as driving or operating complex machinery, should be avoided if these effects occur.

Q: What kind of monitoring is recommended while taking Amixen Plus?

Regulatory documentation requires monitoring for potential risks associated with the NSAID component (Diclofenac). This typically includes monitoring of the patient's blood pressure, cardiovascular status, and liver function through blood tests.

Q: What should I do if a side effect from Amixen Plus does not go away?

Official guidance on adverse events advises that if a patient experiences a new or worsening symptom, or if a known side effect persists or causes concern, they should seek clinical review. Official guidance directs that any new, worsening, or persistent symptom should be reviewed by a healthcare professional.

Q: Does Amixen Plus affect blood sugar levels?

Regulatory labels for the Diclofenac component list hypoglycemia (low blood sugar) as a reported adverse event in the Metabolic and Nutritional Disorders section. This event is documented in regulatory information and indicates a potential risk.

Q: Does Amixen Plus have a 'black box' warning from the FDA or similar agency?

Yes. The NSAID component (Diclofenac) is subject to a Boxed Warning in official regulatory documents. This warning highlights the potential for serious cardiovascular risks (heart attack and stroke) and severe gastrointestinal risks (bleeding and ulceration).

Q: Can Amixen Plus affect my sleep patterns?

Official adverse event reporting for the Diclofenac component lists nightmares as a possible adverse effect in the Nervous System section. This suggests the medicine may indirectly be related to some forms of sleep disturbance.

Q: Can Amixen Plus cause changes in mood or anxiety?

Regulatory labels for the NSAID component (Diclofenac) list psychotic reaction as an adverse event. This is a reported, though infrequent, severe change in mental state or mood. Official guidance states that such changes require clinical review.

Q: What does Amixen Plus mean by 'contraindication'?

According to official regulatory guidance, a contraindication is a specific condition or circumstance that makes the use of the medicine potentially harmful. Regulatory documents state that when a condition is contraindicated, the medicine must be withheld because the risks are considered unacceptable.

Q: What is the half-life of Amixen Plus?

Official pharmacokinetics sections focus on the individual components that make up the combination product. The terminal half-life of the NSAID component (Diclofenac), which relates to how long its anti-inflammatory effects last, is listed as approximately 2 hours.

How should Amixen Plus be stored and disposed of?

How to Store and Dispose of Amixen Plus

Official regulatory documents define strict storage and disposal requirements to maintain the stability of Amixen Plus (Amoxicillin/Diclofenac) solid oral forms.


Storage Conditions

  • Temperature: Store at room temperature, at a maximum temperature not exceeding 30°C (86°F). The product must be kept from freezing.
  • Protection: The medicine must be kept in its tightly closed, original container to protect it from moisture, heat, and light. Do not store in areas with high humidity, such as a bathroom.
  • Child Safety: All medication must be kept out of the reach and sight of children.

Disposal Instructions

Expired or unused Amixen Plus should never be disposed of in household trash or down a toilet or sink. The product must be discarded properly, and patients should consult a pharmacist or healthcare provider regarding local programs for the safe disposal of unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amixen Plus found in:

A-Z Index: